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Abstract
Background: Double sensitization (DS) to bee and vespid venom is frequently observed in the diagnosis of hymenoptera
venom allergy, but clinically relevant DS is rare. Therefore it is sophisticated to choose the relevant venom for specific
immunotherapy and overtreatment with both venoms may occur. We aimed to compare currently available routine
diagnostic tests as well as experimental tests to identify the most accurate diagnostic tool.
Methods: 117 patients with a history of a bee or vespid allergy were included in the study. Initially, IgE determination by the
ImmunoCAP, by the Immulite, and by the ADVIA Centaur, as well as the intradermal test (IDT) and the basophil activation
test (BAT) were performed. In 72 CAP double positive patients, individual IgE patterns were determined by western blot
inhibition and component resolved diagnosis (CRD) with rApi m 1, nVes v 1, and nVes v 5.
Results: Among 117 patients, DS was observed in 63.7% by the Immulite, in 61.5% by the CAP, in 47.9% by the IDT, in 20.5%
by the ADVIA, and in 17.1% by the BAT. In CAP double positive patients, western blot inhibition revealed CCD-based DS in
50.8%, and the CRD showed 41.7% of patients with true DS. Generally, agreement between the tests was only fair and
inconsistent results were common.
Conclusion: BAT, CRD, and ADVIA showed a low rate of DS. However, the rate of DS is higher than expected by personal
history, indicating that the matter of clinical relevance is still not solved even by novel tests. Furthermore, the lack of
agreement between these tests makes it difficult to distinguish between bee and vespid venom allergy. At present, no
routinely employed test can be regarded as gold standard to find the clinically relevant sensitization.
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Introduction
Personal history, skin testing, and detection of sIgE, are the
mainstays of the diagnostic procedure in cases of hymenoptera
venom allergy. Although sensitization to both, honeybee and
vespid venom, is observed in up to 59% of patients [1], clinically
relevant double sensitization (DS) is rare and patients usually react
either to bee or to wasp stings. Therefore, in clinical routine it can
be sophisticated to find the relevant venom for specific immuno-
therapy with common diagnostic tests.
There are several reasons for DS: Generally, a true DS with
antibodies to different bee and vespid venom allergens should be
considered. DS can also be a result of an around 50% sequence
identity of the hyaluronidases in bee and vespid venom. However,
a recent study revealed that the wasp hyaluronidase is only a
minor allergen, and cross-reactivity between vespid and honeybee
venom is not due to protein cross-reactivity, but is mainly caused
by cross-reactive carbohydrate determinants (CCDs) [2]. Gener-
ally, CCDs are a frequent cause for double positivity as CCD-
specific IgE (sIgE) mimics DS in vitro. Asparagine linked
carbohydrate moieties of plant and insect glycoproteins are the
structural basis of CCDs. In hymenoptera venom, these moieties
are found in honeybee venom phospholipase A2 (Api m 1) and
hyaluronidase (Api m 2), in vespid venom only in hyaluronidase
(e.g. Ves v 2). CCD-sIgE is believed to be clinically irrelevant,
although the underlying mechanisms are not completely under-
stood [3,4].
In cases of double positivity, also characteristics of different
methods of serum IgE determination should be regarded:
Depending on the method, frequencies of double-positive test
results vary and range from 10 to 59% [1,5]. In this context,
affinity may play an important role. Affinity is largely determined
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is usually correlated with a rapid dissociation of the complex. To
efficiently activate mast cells or basophils, high affinity antibodies
are required. Most of the current systems of IgE determination use
high doses of allergen for IgE detection due to the binding
competition with specific IgG. As a consequence low affinity IgE
antibodies [6], which are thought to be less relevant for eliciting an
allergic reaction [7], are bound as well. Nevertheless, low affinity
IgE is not completely irrelevant: in the presence of high affinity
IgE it may also activate basophils [8].
The intradermal test is considered not to be influenced by CCDs,
as low affinity antibodies itself are not able to cause positive reactions.
However, clinically irrelevant positive test results at 1,0 mg/ml are
frequently observed [9] and side effects cannot be ruled out [10].
Several studies confirmed the usefulness of the CD63 based
basophil activation test (BAT) as a routine diagnostic tool
[11,12,13] and as a valuable test in patients with inconclusive
tests and history (negative skin tests, undetectable sIgE or unknown
stinging insect) [14,15]. Compared with the IgE determination in
the serum, BAT has the advantage of demonstrating functional
responses: Positive test results will only occur after successful cross-
linking of two identical FceRI-bound IgE antibodies and not by
monovalent binding like in IgE assays.
Recently, the component resolved diagnosis (CRD) has been
described as useful tool to facilitate the diagnosis of bee and vespid
venom allergy [1,16]. Nevertheless, in these studies only rApi m 1
and rVes v 5 were employed to discriminate between true and
CCD-based DS. But it is crucial to additionally determine Ves v 1,
otherwise 10–13% of vespid venom allergic patients will not be
diagnosed due to a mono-sensitization to Ves v 1 [1,2].
Treatment of double positive patients with both venoms is a
pragmaticway,butfrequentlynotjustifiedbecause ofasymptomatic
sensitization or cross-reactions caused by CCDs. Therefore there is
still need for a test which is able to discriminate between clinically
relevant or irrelevant sensitization in order to reduce the burden of
treatment and to keep therapy as cost-efficient as possible.
In clinical routine, we observed a high frequency of double
positivity in the IgE determination by the CAP system (Im-
munoCAPH, Phadia, Uppsala, Sweden) and a markedly lower
frequency of double positive results obtained by the BAT. Giving
this background, we initiated a prospective study to evaluate the
usefulness of new diagnostic approaches for the routine diagnosis
of hymenoptera venom allergy. For this purpose, we aimed to
compare the outcomes of the BAT with the IDT (intradermal test)
as well as with three different methods of IgE determination (CAP,
ADVIA (ADVIA CentaurH, Siemens, Tarrytown, NY, USA),
Immulite (Immulite 2000H, Siemens, Tarrytown, NY, USA))
regarding the frequency of double positive results. To study IgE
binding patterns, western blot (WB) inhibition as well as a CRD
with native and recombinant Api m1, Ves v 1 and Ves v 5 were
performed in all patients with DS.
Methods
Patients
One hundred and seventeen consecutive patients, who had been
admitted to our outpatient clinic because of systemic allergic
reactions with at least generalized skin symptoms after a
hymenoptera sting, were screened. Their personal history was
taken and the current standard diagnostic procedures (intradermal
tests, IgE determination by CAP) were performed. As wasp and
European hornet belong to the family of Vespidae and their
venoms contain the same major antigens, we did not differentiate
between these genera. Additionally, sIgE was determined by
ADVIA, and the Immulite; basophil responsiveness was analyzed
by a CD63 based BAT. In 72 patients showing specific IgE to
honeybee and vespid venom in the CAP system, IgE patterns were
determined by WB inhibition and CRD. This study was approved
by the ethics committee of the Medical University of Graz.
Personal history
According to the modified classification of Ring and Messmer,
generalized skin symptoms such as flush, urticaria and angioedema
were classified as grade I reaction. Mild to moderate pulmonary,
cardiovascular or gastrointestinal symptoms were rated as grade II
reaction. Bronchoconstriction, emesis, anaphylactic shock, and
loss of consciousness were classified as grade III reaction.
Reagents
All laboratory reagents were obtained from Merck (Whitehouse
Station, NJ, USA) or Sigma-Aldrich (St Louis, CA, USA) unless
otherwise specified. Dulbecco’s modified phosphate-buffered
saline (PBS; with or without Ca
2+ and Mg
2+) was purchased from
Gibco-Invitrogen (Carlsbad, CA, USA). CellFix and anti-CD123
(PE-conjugated) were supplied by Becton Dickinson (Franklin
Lakes, NJ, USA). Antibodies to HLA-DR (PC5-conjugated),
CD63 (FITC-conjugated), and monoclonal antibodies to IgE were
purchased from Beckman Coulter (Fullerton, CA, USA). Honey-
bee and vespid venom for the skin tests and BAT were purchased
from ALK-Abello ´ (Hørsholm, Denmark). Honeybee venom and
vespid venom sac extracts (mixture of Vespula vulgaris and germanica)
were kindly provided by Vespa Laboratories, PA, USA.
Skin tests
The nature of sensitization was confirmed by standardized end-
point titration IDTs (0.02 mL of 0.001, 0.01, 0.1 and 1 mg/mL
solution) using purified honeybee and vespid venom extracts. IDTs
were considered to be positive in the presence of a wheal $5m m
in diameter and erythema.
Determination of sIgE and tIgE
Specific and total IgE antibody levels in the patients’ serum
were measured using ImmunoCAP 1000 (Phadia, Uppsala,
Sweden), ADVIA Centaur, and Immulite 2000 (both: Siemens,
Tarrytown, NY, USA) according to the manufacturer’s instruc-
tions. The CRD with native and recombinant nApi m 1 and rApi
m 1 was done on the ImmunoCAP 1000. Diagnosis with the major
wasp allergens nVes v 1 and nVes v 5 as well as with nApi m 1 was
done on the ADVIA Centaur platform by the Department of I+D,
ALK-Abello ´, Madrid, Spain.
Basophil activation test (BAT)
BAT was performed as previously described [17]. In brief,
EDTA whole blood was stained with anti-CD123 PE-conjugated
antibody (1:50), anti-HLA-DR PC5-conjugated antibody (1:50)
and anti-CD63 FITC-conjugated antibody (1:50). Basophil
reactivity was measured using serial dilutions of honeybee or
vespid venom (1000, 100, 10, 1 ng/mL) or serial dilutions of anti-
IgE antibody (1:10–1:1000 dilution).
Finally, cell samples were analyzed by three-color flow
cytometry (FC 500, Beckman Coulter). Basophils were identified
as a single population of cells that stained positive for CD123 (FL-
2) and negative for HLA-DR (FL-4). Up-regulation of CD63
expression was indicated by an increase in fluorescence in the FL-1
channel. Acquisition was terminated after 500 basophil target
events. An approximately 2.5-fold increase in the number of
activated basophils (.25%) as compared with the negative control
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considered to be a positive response. This threshold was
determined by ROC analysis as described earlier [12].
Western blots and western blot inhibition
Honeybee venom and vespid venom were separated by SDS-
PAGE using 13.5% resolving and 5.7% stacking gels under
reducing conditions using dithiothreitol and heat. Electrophoret-
ically separated proteins were blotted onto nitrocellulose mem-
branes and single strips (6 mg venom/strip) blocked with PBS
buffer (50 mM sodium phosphate, pH 7.5, 0.5% Tween 20, and
0.05% NaN3) containing 0.5% BSA at room temperature for 1 h.
Subsequently, strips were incubated overnight with 1 mL of serum
(diluted 1:5–1:10) at 4uC under continuous shaking. After
washing twice with PBS buffer for 30 min, bound IgE was
detected by
125I-labelled rabbit anti-human IgE (Phadia, Uppsala,
Sweden). After overnight incubation at room temperature, washed
and dried strips were exposed to a high-performance autoradiog-
raphy film (Hyperfilm MP, Amersham, England) at 270uC for 5–
10 days.
To discriminate between IgE specific for peptide or carbohy-
drate epitopes, antibody binding to CCDs was inhibited by
preincubating sera with 5 mg/mL of MUXF-BSA as done in
previous studies [18]. MUXF-BSA is a synthetic glycoprotein
obtained by coupling purified N-glycans from pineapple stem
bromelain to BSA [19], whereby MUXF (or more exactly
MUXF
3) stands for the glycan structure Mana1-3(Xylb1-
2)Manb1-4GlcNAcb1-4(Fuca1-3)GlcNAcb1.
Data analysis
All data are expressed as medians (25%; 75% percentiles) on the
rawscale, unlessotherwiseindicated.Datawere tested for normality
using the Kolmogorov-Smirnov test. Continuous variables were
analysed by the Kruskal Wallis test; categorical variables were
compared by the Chi-square test or Fisher’s exact test. To check
agreement between the tests, Cohen’s kappa coefficient was
calculated. The level of significance was set at p,0.05. The SPSS
17.0 software (SPSS Inc, USA) was used for statistical analysis.
Results
History and demographic data
One hundred and seventeen patients with a unequivocal history
of a systemic sting reaction were included in the study. Fifty-eight
(49.6%) were female, and 59 (50.4%) male. Median age was 42.0
(30.5; 53.0) years; the majority of patients (45.3%) were in the age
group between 30 and 50 years.
Four patients (3.4%) had a history of grade I reactions, 80
patients (68.4%) had experienced grade II reactions and 33
patients (28.2%) grade III reactions. Thirty-eight (32.5%)
identified a honey bee as culprit insect, 55 (47.0%) a wasp, and
24 (20.5%) could not identify the insect. None of the patients
reported systemic sting reaction after both, honeybee and wasp
stings.
Double sensitization
Frequency of DS differed considerably among performed
diagnostic tests and ranged from 63.7% with the Immulite to
17.1% with the BAT (Figure 1). Generally, agreement of tests was
fair with 53.1% (kappa 0.318; p,0.0001)
Differences between mono and double sensitized as well
as double negative patients
In all tests except in the BAT, tIgE levels were up to 2.3-fold
higher in double sensitized patients compared to mono sensitized
patients. Conversely, patients with double negative results had
lower tIgE levels compared to mono or double sensitized patients
(Table 1). The comparison of mean age between the three
categories revealed no significant difference.
Additionally, regression analysis to check the influence of the
severity of sting reaction, sex, age and tIgE on DS was performed:
The frequency of DS was influenced by tIgE levels in the CAP
(e
b 1.005, p=0.035) and ADVIA (e
b1.003, p=0.048). Addition-
ally, higher age of the patients was associated with a lower
frequency of DS in the CAP (e
b 0.966, p=0.038). The rate of DS
in the BAT, IDT, and Immulite was not influenced by the tested
variables.
Figure 1. Frequency of double sensitization. The rate of DS in 117 consecutive patients differed significantly (p,0.0001) and ranged from 17.1%
with the BAT to 63.7% with the Immulite.
doi:10.1371/journal.pone.0020842.g001
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CAP
IgE determination by CAP yielded together with the Immulite
the highest frequency of double positive results. As the CAP system
is widely used, and this group of 72 patients comprised virtually all
patients with double positive results in supplemental tests, further
analysis regarding the individual IgE pattern was done in this
subgroup.
First, the rate of DS of each commercially available and
experimental test was determined to identify the most specific test
to reduce the high frequency of clinically not relevant DS. As
expected, CRD analysis solely done with the native main allergen
components nApi m 1, nVes v 1, and nVes v 5 led to a slightly
reduced, but still high frequency of DS. The use of non-
glycosylated rApi m 1, nVes v 1 and nVes v 5 reduced the
frequency considerably by 49.0%. Similar lower rates of DS were
observed with the WB inhibition, ADVIA and BAT, while the
Immulite and the IDT revealed high frequencies of DS (Figure 2).
IgE patterns of CAP double sensitized patients with WB
inhibition
The WB was not interpretable in 11 of 72 patients. Among the
remaining patients, true DS was diagnosed in 24 of 61 patients,
putative cross-reactivity due to hyaluronidase in 6 patients, and
double positive results caused by CCD alone in 31 patients (typical
IgE patterns see Figure 3).
CRD in CAP double sensitized patients
>As at the time when the study was performed rApi m 1 was
not available for the ADVIA, and vice versa nVes v 1 and nVes v 5
not for the CAP, rApi m1 was determined with the CAP and nVes
v 1 and nVes v 5 with the ADVIA. To check compatibility, nApi
m 1 was determined on the CAP as well as ADVIA. In contrast to
the IgE determination with bee and vespid extracts, the test results
with native components were coinciding with 92.3%, assuming an
almost perfect agreement.
Finally, CRD with recombinant and native allergens was
performed in 64 of 72 CAP double positive sera; four patients were
negative for the tested bee and vespid venom allergens (Figure 4
A+B). There was a substantial agreement between the WB and the
CRD for Api m 1 with 88.5% (kappa 0.770, p,0.0001), and Ves v
5 with 87.7% (kappa 0.744, p,0.0001). The agreement for Ves v
1 was only fair with 71.9% (kappa 0.377, p=0.005).
BAT compared to CRD and WB inhibition in CAP double
sensitized patients
Beside the component-specific tests (CRD, WB) only the BAT
and ADVIA showed a comparable low frequency of DS despite
the use of conventional allergen extracts. As ADVIA is no longer
available, further analysis was only done with the BAT in 72
patients; 11 were negative for both venoms (Figure 5). Notewor-
thy, in 11 patients with DS in the CRD, basophils were only
activated by one venom in the BAT. Conversely, 7 BAT double
positive patients showed only a mono sensitization in the CRD.
There was a similar picture with the WB inhibition: 13 double
Table 1. Correlation between total IgE (kU/L) and test results.
Double
sensitization
Mono
sensitization Double negative p
BAT 54.3 (24.5; 217.3) 64.7 (36.9; 151.0) 58.9 (22.7; 112.0) 0.463
ADVIA 117.0 (50.9; 397.6) 51.7 (30.3; 123.4) 35.9 (10.4; 142.4) 0.008
IDT 88.7 (45.2; 252.0) 53.9 (29.4; 103.5) 35.3 (8.7; 69.0) 0.014
CAP 90.8 (48.9; 230.0) 43.3 (29.1; 64.2) 28.0 (10.6; 66.0) 0.000
Immulite 87.2 (42.6; 246.0) 51.5 (19.6; 87.5) 8.0 (2.7; 95.6) 0.006
In all tests except in the BAT, double sensitized patients showed higher levels of
total IgE (tIgE) compared to mono sensitized patients. Conversely, double
negative patients had lower tIgE levels compared to mono- and double
sensitized patients.
doi:10.1371/journal.pone.0020842.t001
Figure 2. Frequency of double sensitization in supplemental tests in 72 CAP double positive patients. n CRD: native component
resolved diagnosis with nApi m 1, nVes v 1, nVes v 5. r/n CRD: combined component resolved diagnosis with recombinant rApi m 1, and native nVes v
1, nVes v 5. BAT (p=0.324) and ADVIA (p=0.874) showed a similar frequency of DS compared to WB inhibition and r/n CRD, although they were
performed with native venom extracts.
doi:10.1371/journal.pone.0020842.g002
Diagnostic Problems in Hymenoptera Venom Allergy
PLoS ONE | www.plosone.org 4 June 2011 | Volume 6 | Issue 6 | e20842positive patients in the WB inhibition were only positive to one
venom in the BAT and 7 BAT double positive patients showed
only a mono sensitization in the WB inhibition. Generally, results
of the BAT were in fair agreement with those of the CRD
(Figure 6).
sIgE to MUXF (CCD)
Determination of sIgE to MUXF in the CAP (CCD-IgE) was
not appropriate to distinguish between true DS and CCD based
DS. 16 of 30 patients with true DS in the WB (sensitization to
major allergens or hyaluronidase) had detectable sIgE to MUXF
and conversely, only 16 of 31 patients with a verified CCD-based
DS by the WB inhibition had sIgE to MUXF (Figure 7).
Additionally, also 15 of 25 (60.0%) patients with true DS
verified by CRD had sIgE to MUXF.
Double positive results in CCD-dependent DS
CCD dependent DS was verified by WB inhibition in 31
patients. Depending on the test, frequency of DS ranged from
12.0% to 89.3% in these patients (Figure 8).
Figure 3. Frequency of typical IgE patterns obtained by western blot inhibition in CAP double sensitized patients. CCD: cross-reactive
carbohydrate determinants, True DS: true double sensitization, WB: western blot, WB-I (western blot inhibition): To discriminate between IgE specific
for peptide or carbohydrate epitopes, antibody binding to CCDs was inhibited by preincubating sera with MUXF-BSA. Among these patients the
majority of DS was CCD-dependent. DS due to protein components of hyaluronidases played a minor role. n=61.
doi:10.1371/journal.pone.0020842.g003
Figure 4. Component resolved diagnosis in CAP double sensitized patients. A Sensitization to bee and/or vespid venom in the
component resolved diagnosis. Positive for bee venom: rApi m 1
pos / nVes v 1
neg and nVes v 5
neg; Positive for wasp venom: rApi m 1
neg / nVes v 1
and/or nVes v 5
pos; DS: rApi m 1
pos / nVes v 1 and/or nVes v 5
pos. n=60. B Sensitization pattern in vespid venom allergic patients. The
majority of patients were sensitized to both vespid major allergens (nVes v 1 and nVes v 5). Nevertheless, a considerable proportion had a mono
sensitization to nVes v 1 or nVes v 5. n=31.
doi:10.1371/journal.pone.0020842.g004
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Positive test results to bee and vespid venom are frequently
observed in the routine diagnosis of hymenoptera venom allergy
and raise problems to determine the causative insect for a correct
treatment. Treatment with two venoms is generally accepted in
patients with severe sting reactions and inconclusive test results.
Nevertheless, there is a high risk of overtreatment, and even for a
novel sensitization, if positive results are unspecific and caused by
weakness of diagnostic methods or by CCDs.
In the current study, we performed an extensive evaluation of
various conventional, recently established, and experimental test
methods. We could demonstrate that the BAT had the lowest
frequency of DS and thus correlated best with the patients’ history.
Nevertheless, the BAT showed double positive results in nearly
one third of patients with CCD-based DS, and vice versa was
sometimes only positive for one venom in patients with DS in the
WB inhibition and CRD. CCDs can lead in vitro to a stimulation of
basophils [20,21] and the question of clinical relevance of these
positive results remains still unanswered. Conversely, even a true
(double-) sensitization must not be clinically relevant [22,23]. In
this case, the BAT as functional test may be helpful to find the
culprit venom. IgE determination by the ADVIA also resulted in a
low frequency of DS, even though it was slightly higher compared
to the BAT. However, the ADVIA platform is no longer available
for routine diagnosis as it has been taken off the market despite of
its revolutionary concept of IgE determination and its excellent
performance. Additionally, we could show that the intradermal
test was not beneficial in the discrimination between mono- and
double sensitization because it revealed DS in as much as 69% of
patients. This may either reflect false-positive reactions due to
histamine liberating substances or toxic effects of the venom, as
well as some mast cell activation by CCDs at very high venom
concentrations (1 mg/ml). As expected, the CRD with recombi-
nant and native CCD-free allergens discriminated well between
CCD based and true DS, and hence represents a clear step
forward in the diagnosis of hymenoptera venom allergy.
Importantly, the sensitization patterns of the CRD correlated well
with those of the western blot. Nevertheless, the CRD revealed a
markedly lower frequency of honey bee sensitization compared to
BAT and WB which could indicate an insufficient sensitivity of
rApi m 1 and the need for additional honeybee venom allergens.
Clinically relevant DS is rarely observed: in a large European
(EAACI) multicenter study regarding side-effects during immuno-
therapy only 58 of 840 (6.9%) were treated with two venoms [24].
At the same time, asymptomatic sensitization is observed in 27.1 to
66.7% of the general population depending on the test method of
IgE determination and tIgE levels [5,23].
Depending on the methods and venoms used, the specificity of
serum IgE determination ranges between 60% and 94% [12].
Leading manufacturers of automated lab systems generally
postulate high sensitivities and specificities for their IgE determi-
nation. However, the studies leading to these results must be
viewed critically: control subjects with high tIgE levels, positive
Figure 5. Frequency of sensitization to bee and/or vespid
venom in the basophil activation test. n=61.
doi:10.1371/journal.pone.0020842.g005
Figure 6. BAT results in relation to western blot inhibition and component resolved diagnosis. Although BAT was performed with native
venom extracts, frequency of mono- and double sensitization was comparable with component based methods. Results of the BAT were in fair
agreement with those of the CRD (60.0%, kappa 0.373, p,0001) and WB (59.6%, kappa 0.377, p,0001). Interestingly, the frequency of honey bee
sensitization obtained with the CRD was markedly lower compared to BAT and WB, which could indicate a lower sensitivity of rApi m 1.
doi:10.1371/journal.pone.0020842.g006
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to obtain optimum specificities [25,26].
Generally, methods of serum IgE determination differ consid-
erably and therefore results are difficult to compare. In CAP, the
allergen is bound to a solid cellulose sponge matrix. After
incubation with the patient’s serum sIgE and also specific IgG is
bound to the covalently coupled allergen. To quantify sIgE levels,
sIgE is detected by enzyme-labeled anti-IgE. To minimize
competition between the low quantity of IgE and the substantial
quantity of IgG a very high amount of allergen is bound to the
immunosorbent. Therefore also low-affinity cross-reacting sIgE
like those to CCDs with questionable clinical relevance are
detected. The same might be valid for the Immulite, although it
depends on another principle: In brief, ligand-labeled liquid
allergens first bind to anti-ligand-coated polystyrene beads; after
adding the patient’s serum, sIgE is bound to the allergen. Again,
sIgE is detected by anti-IgE. High doses of allergen to avoid
displacement of sIgE antibodies in both tests would explain the
similar frequency of DS with 61.5% and 63.7%, respectively.
The concept of the ADVIA is completely different to exclude
interference with non-IgE antibodies like IgG. Anti-IgE is coupled
to paramagnetic particles that catch all IgE in the serum. Then
biotin-labeled allergen is added and bound sIgE reacts with the
allergen in suspension. Finally sIgE is detected indirectly with
acridinium ester labeled streptavidin [27]. The main advantage of
this approach is that much less allergen is needed and therefore the
affinity of sIgE is better considered. This explains the good
performance of the ADVIA despite of the native venom extracts
used.
The IDT and the BAT have the advantage of demonstrating
functional responses as positive results usually only occur after
cross-linking of two identical cell-bound IgE antibodies. Never-
theless, we observed a considerable difference in the occurrence of
DS: The IDT was positive for bee and vespid venom in 47.9% of
patients compared to 17.1% double positive results obtained by
the BAT. The high frequency in the IDT might be explained by
the irritant effect of the venom at higher doses and, as mentioned
earlier, by the activation of some mast cells by CCDs at very high
venom concentrations. On the other hand, the low rate of DS in
the BAT with native venom extracts supports the hypothesis, that
the BAT is able to demonstrate a functional response without
possible irritant reactions as seen in the IDT and without
considerable influence of CCDs on test results as obtained with
Figure 7. Determination of sIgE to MUXF (CCD) was not
appropriate to distinguish between true and CCD-based
double sensitization. Patients with true DS in the WB (sensitization
to major allergens or hyaluronidase) had detectable sIgE to MUXF and
conversely, patients with a verified CCD-based DS by the WB inhibition
had no detectable sIgE to MUXF. As the coincidence of true DS and
detectable sIgE to MUXF was high, results could be misinterpreted and
true DS could be easily overlooked.
doi:10.1371/journal.pone.0020842.g007
Figure 8. Double positive results in CCD-dependent double sensitization. CCD-dependent DS was verified with WB inhibition in 31
patients. The Immulite and IDT revealed the highest rates of DS in these patients (p,0.001; n=24–31).
doi:10.1371/journal.pone.0020842.g008
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were reported with the CD203c based BAT [28], this is contrary
to our findings. This extraordinary high rate of DS might not
depend on the different activation marker CD203c, but on an
internationally uncommon protocol and unusual interpretation of
results. Nevertheless, there still remain a few open questions: In
our study, the BAT showed in 29% of patients with a verified
CCD-based DS double positive results and vice versa the BAT was
sometimes only positive for one venom despite that the CRD and
WB inhibition revealed double positive results, respectively.
The role of CCDs for eliciting clinical symptoms is still unclear.
There are several hypotheses why sIgE to CCDs are not relevant,
one of them is that patients are constantly exposed to these
carbohydrate structures and therefore produce blocking IgG4
antibodies, comparable with the effect of immunotherapy [4]. This
might explain that basophils can be activated in the BAT, but not
in vivo.
The application of recombinant or native CCD-free allergens
will be a considerable progress in the diagnosis of hymenoptera
venom allergy. nApi m 1 showed clearly more positive results
compared to rApi m 1, again indicating the crucial role of CCDs
in DS. Thus makes it inevitable to use components which are
CCD-free by nature or to produce recombinant allergens without
CCDs. Importantly, the generally accepted use of sIgE to CCD as
marker for CCD-based cross-reactivity has to be viewed critically
and must be considered obsolete. As shown in the WB, the
presence of IgE to CCDs does not exclude true DS, therefore true
DS can be easily overlooked, which may result in fatal reactions.
To summarize, BAT and CRD showed the lowest rates of DS,
but inconsistent results were common. Although each test alone
seems to help finding the clinically relevant venom, it is still
unclear which test represents the most accurate. Therefore, studies
with sting challenges to check the accurate negative predictive
value of the BAT and CRD in otherwise double sensitized patients
would be preferable. At present, no routinely employed test can be
regarded as gold standard to distinguish between clinically relevant
bee and wasp venom sensitization.
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